PTC Therapeutics
PTCT
164 hedge funds and large institutions have $1.66B invested in PTC Therapeutics in 2018 Q4 according to their latest regulatory filings, with 19 funds opening new positions, 70 increasing their positions, 48 reducing their positions, and 35 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 70 | Existing positions reduced: 48
3.46% more ownership
Funds ownership: 93.19% → 96.65% (+3.5%)
9% less funds holding
Funds holding: 180 → 164 (-16)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
24% less capital invested
Capital invested by funds: $2.2B → $1.66B (-$536M)
25% less call options, than puts
Call options by funds: $11.9M | Put options by funds: $15.8M
46% less first-time investments, than exits
New positions opened: 19 | Existing positions closed: 35
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$49.5M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$47.4M |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$27.6M |
| 4 |
Renaissance Technologies
New York
|
+$26.6M |
| 5 |
Franklin Resources
San Mateo,
California
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
-$48.7M |
| 2 |
Balyasny Asset Management
Chicago,
Illinois
|
-$32.9M |
| 3 |
D.E. Shaw & Co
New York
|
-$27.4M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$23.5M |
| 5 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$11.7M |
PTCT Hedge Fund Activity: Q4 2018 in Review
164 of the 4,489 institutional investors tracked by Wall St. Rank reported a position in PTC Therapeutics (PTCT) for Q4 2018, worth a combined $1.66B — down 24% from $2.2B a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of PTCT and 19 opened new positions — a net loss of 16 holders — while 48 trimmed existing stakes and 70 added.
The largest buyer was Point72 Asset Management, adding an estimated $49.5M. The largest seller was RTW Investments, cutting an estimated $48.7M.
- 164 institutional investors held PTC Therapeutics (PTCT) as of Q4 2018, down from 180 in Q3 2018.
- Funds reported $1.66B of PTC Therapeutics stock for Q4 2018, down 24% quarter-over-quarter.
- 19 funds opened new PTC Therapeutics positions in Q4 2018 and 35 closed out, a net change of -16 holders.
- The largest PTC Therapeutics buyer in Q4 2018 was Point72 Asset Management, an estimated $49.5M added.
- The largest PTC Therapeutics seller in Q4 2018 was RTW Investments, an estimated $48.7M sold.
Based on aggregated 13F filings for Q4 2018.